IECM
JAZZ icon

Intrinsic Edge Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Intrinsic Edge Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,000
Closed -$1.43M – 255
2020
Q3 		$1.43M Buy
+10,000
New +$1.24M 0.1% 205

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Intrinsic Edge Capital Management's JAZZ Position: Q4 2020 in Review

Intrinsic Edge Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2020, closing a stake of 10,000 shares — an estimated $1.43M sold.

Intrinsic Edge Capital Management first reported a position in JAZZ in Q3 2020 and held it in 1 quarter. The position peaked at $1.43M in Q3 2020. 437 funds tracked by Wall St. Rank hold JAZZ as of Q4 2020.

  • Intrinsic Edge Capital Management reported no remaining Jazz Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 10,000 Jazz Pharmaceuticals shares in Q4 2020, an estimated $1.43M.
  • Intrinsic Edge Capital Management first reported a position in Jazz Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Intrinsic Edge Capital Management's Jazz Pharmaceuticals position peaked at $1.43M in Q3 2020.
  • 437 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2020.

Based on Intrinsic Edge Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.